Oral vs. IV Ketamine: Comparative Research

The question patients and clinicians most often want answered is direct: Is ketamine tablet as effective as IV? The honest answer is nuanced: ketamine tablet is probably less effective for acute antidepressant induction, but it may be similarly effective (or more practical) for maintenance, and produces a distinct pharmacological experience that may confer unique benefits for some patients.

The Fundamental Methodological Challenge

Comparing oral to IV ketamine directly is methodologically difficult because:

1. No blinded head-to-head RCTs exist: No study has randomized patients to oral vs. IV ketamine with identical clinical endpoints in a blinded fashion. Blinding is essentially impossible — the routes have completely different experiential profiles.
2. Different populations: IV ketamine is typically used for severe acute TRD; ketamine tablet is often used for maintenance or milder cases. Population differences confound any comparison.
3. Different dosing philosophies: IV protocols typically target 0.5 mg/kg over 40 minutes to achieve specific plasma levels. Oral dosing varies widely between protocols (0.5–5 mg/kg). See our dosing guide for more on oral dose ranges.
4. Different therapeutic endpoints: IV is typically measured at Day 1 and Day 7 post-infusion; oral is typically measured over weeks of treatment.

Given these challenges, the comparison is built from indirect evidence — reviewing separate bodies of literature and extracting comparable estimates.

Acute Antidepressant Response: IV Likely Superior

IV Ketamine Evidence

Meta-analyses of IV ketamine for TRD consistently report:

• Response rates: 50–70% at 24 hours post-infusion
• Remission rates: 25–40% at 24 hours
• Number needed to treat (NNT): approximately 3–5
• Consistency: Repeated demonstrations across multiple independent research groups and geographic locations

These are among the highest response rates documented for any treatment in TRD, achieved within 24 hours.

Ketamine Tablet Evidence

Comparable data from ketamine tablet:

• Response rates: 50–77% at Day 7 (but open-label, without blinding)
• Controlled trial response rates: approximately 40–60% in the limited RCT data available
• Onset: Antidepressant effects typically emerge within 24–72 hours (versus hours for IV)
• Consistency: Generally supported but with more variability due to fewer and lower-quality studies

Comparative assessment: The IV literature is substantially more robust in study quality (larger samples, blinded designs, consistent protocols). The oral response rates appear numerically similar but are based on weaker evidence (primarily open-label studies). It is reasonable to conclude that IV ketamine has a stronger evidence base for acute antidepressant response, and likely produces more reliable acute response at the individual patient level.

Maintenance Response: Oral May Be Equivalent or Superior

The Maintenance Phase

While IV ketamine produces more reliable acute response, it must be repeated indefinitely to maintain that response in most patients. Maintenance IV ketamine (booster infusions every 2–8 weeks) is used in clinical practice but has its own limitations:

• Cost: $400–$800 per booster infusion, rapidly accumulating to $5,000–$20,000/year
• Burden: Requires clinic visits with transportation and 2–4 hour time commitment
• Access: Not available in many geographic areas

Ketamine Tablet for Maintenance

Several clinical programs and the available follow-up studies suggest that ketamine tablet may be as effective as IV booster infusions for maintenance purposes:

• A transition protocol from IV induction to oral maintenance has been adopted by some clinical programs, reporting similar relapse rates as continuing IV maintenance
• The lower peak plasma levels of ketamine tablet may be sufficient to maintain neuroplastic gains achieved during IV induction
• Norketamine's longer half-life and accumulation with oral dosing may provide more sustained receptor interactions than intermittent IV booster infusions

Comparative assessment: There is insufficient direct evidence to definitively conclude that oral maintenance is equivalent to IV maintenance. However, the practical case for using ketamine tablet for maintenance (after IV induction or as standalone maintenance) is compelling based on cost, access, and available observational data.

Pharmacokinetic Comparison

Understanding the pharmacokinetic differences provides mechanistic context for the clinical comparison:

The most striking difference is the norketamine:ketamine ratio. Oral dosing is fundamentally a different pharmacological exposure — one dominated by norketamine and its downstream metabolites (HNK) rather than ketamine itself.

Dose Equivalence: A Complex Question

"How much ketamine tablet equals one IV infusion?" is a question without a clean answer because the two routes produce fundamentally different pharmacological profiles, not simply different amounts of the same experience.

If the question is "what oral dose produces the same plasma ketamine Cmax as IV 0.5 mg/kg?":

• IV 0.5 mg/kg (35 mg for 70 kg patient) achieves Cmax of approximately 500–1,000 ng/mL
• Ketamine tablet at 250–500 mg (20–25% bioavailability = 50–125 mg reaching circulation) achieves Cmax of approximately 50–200 ng/mL
• To achieve similar plasma peaks: approximately 5–8x higher oral dose would theoretically be needed — doses that produce strong dissociation and are not practical for outpatient use

This illustrates that oral and IV ketamine cannot simply be dose-converted: they are used at different plasma levels for different clinical purposes.

Tolerability Comparison

IV Ketamine Tolerability

• Strong dissociation at 0.5 mg/kg infusion rate — essentially all patients experience significant dissociation
• Cardiovascular effects: Documented blood pressure and heart rate elevation requiring monitoring
• Nausea: Common; prophylactic anti-emetics used routinely
• Requires clinic-based administration and 1–2 hour monitoring
• Very low risk of serious adverse events in clinical settings

Ketamine Tablet Tolerability

• Variable dissociation depending on dose; can be titrated to minimize dissociation
• Cardiovascular effects: Present but typically less acute than IV due to slower absorption
• Nausea: Common, particularly at onset; may be reduced by food or anti-emetics
• Can be administered at home in appropriate patients
• Very low risk of serious adverse events at therapeutic doses

Comparative assessment: Ketamine tablet is more tolerable for ongoing maintenance use due to the ability to minimize acute dissociation through lower dosing. IV is more predictable for acute sessions but is more burdensome and cannot be used at home.

Clinical Recommendation Framework

The evidence supports a rational clinical algorithm:

1. Acute antidepressant induction: IV ketamine (or Spravato) produces more reliable and rapid acute response; preferred for severe acute episodes
2. Maintenance after IV induction: Transition to ketamine tablet for maintenance; reduces cost and burden while (in most patients) maintaining the neuroplastic gains from IV treatment
3. Outpatient initiation in moderate TRD: Ketamine tablet alone, without prior IV, is a reasonable first-line ketamine approach for patients with moderate (not severe) TRD or those unable to access IV clinics
4. Pain management: Ketamine tablet is preferred for chronic pain (continuous dosing is more practical than repeated IV infusions)
5. Maintenance in remitted patients: Ketamine tablet for long-term maintenance is the most practical choice for most patients who achieve remission

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
• WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches